

Future Medicine FM101-Oral Glaucoma Treatment

Future Medicine Co., Ltd.



OPHTHALMOLOGY	Phase 2
Product Type	Small molecule
Indication	Glaucoma
Target	A3AR
MoA(Mechanism of Action)	A3AR Modulator
Competitiveness	<ul style="list-style-type: none"> • Most of the existing glaucoma treatments are in the form of eye drops and cause local side effects such as congestion of eye mucosa and irritation of the eye mucosa. • The elderly population has difficulty in accurately dosing eye drops. Also, 65% of patients contaminated the eye drop container occurred due to hand tremors. • When two or more eye drop treatments are used in combination, the intraocular pressure lowering effect is lower than expected due to non-compliance with the second drug administration interval. • There are no drugs that have a protective effect against damage to the optic nerve caused by elevated intraocular pressure. • FM101 is a potential new drug that could effectively lower intraocular pressure while providing convenience to administration due to its oral availability. Furthermore, FM101 has a lower concern about topical side effects compared to topical agents being used as a standard of care.
Development Stage	Phase II
Route of Administration	Oral